CGTX Projected Dividend Yield
Cognition Therapeutics Inc ( NASDAQ : CGTX )Cognition Therapeutics is a clinical-stage biopharmaceutical company. Co. is developing a pipeline of small molecule product candidates that are designed to target the o-2 (sigma-2) receptor (S2R) complex, a key regulator of the cellular damage response for diseases such as Alzheimer's disease, dry Age-Related Macular Degeneration (AMD), geographic atrophy (a form of dry AMD), and other conditions. Co.'s main product candidate, CT1812, is an orally delivered, small molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex. Co. is initially focused on the development of CT1812 for the treatment of AD by targeting the accumulation of B-amyloid. 20 YEAR PERFORMANCE RESULTS |
CGTX Dividend History Detail CGTX Dividend News CGTX Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |